$XBIT
XBiotech Inc.

2017 Q1 Form 10-Q Financial Statement

#000117184317002928 Filed on May 10, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.080M $2.440M
YoY Change -14.75% 71.83%
% of Gross Profit
Research & Development $8.188M $7.812M
YoY Change 4.81% 15.15%
% of Gross Profit
Depreciation & Amortization $296.0K $179.0K
YoY Change 65.36% 8.48%
% of Gross Profit
Operating Expenses $10.27M $10.25M
YoY Change 0.22% 24.9%
Operating Profit -$10.27M -$10.25M
YoY Change 0.22% 24.9%
Interest Expense -$290.0K -$10.00K
YoY Change 2800.0% -111.11%
% of Operating Profit
Other Income/Expense, Net -$292.0K -$9.000K
YoY Change 3144.44% -109.89%
Pretax Income -$10.56M -$10.26M
YoY Change 2.92% 26.51%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$10.56M -$10.26M
YoY Change 2.98% 26.41%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$317.2K -$317.7K
COMMON SHARES
Basic Shares Outstanding 32.29M
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $54.60M $78.20M
YoY Change -30.18% 49.81%
Cash & Equivalents $54.63M $78.23M
Short-Term Investments
Other Short-Term Assets $2.500M $1.600M
YoY Change 56.25% 6.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $57.09M $79.84M
YoY Change -28.5% 48.4%
LONG-TERM ASSETS
Property, Plant & Equipment $30.53M $7.715M
YoY Change 295.74% 57.45%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $30.53M $21.42M
YoY Change 42.52% 337.2%
TOTAL ASSETS
Total Short-Term Assets $57.09M $79.84M
Total Long-Term Assets $30.53M $21.42M
Total Assets $87.62M $101.3M
YoY Change -13.48% 72.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.697M $4.846M
YoY Change -44.35% 67.1%
Accrued Expenses $2.626M $1.717M
YoY Change 52.94% 90.78%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.323M $6.563M
YoY Change -18.89% 72.71%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $5.323M $6.563M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $5.346M $6.583M
YoY Change -18.79% 73.24%
SHAREHOLDERS EQUITY
Retained Earnings -$194.0M -$140.9M
YoY Change 37.66%
Common Stock $276.1M $235.8M
YoY Change 17.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $82.27M $94.68M
YoY Change
Total Liabilities & Shareholders Equity $87.62M $101.3M
YoY Change -13.48% 72.51%

Cashflow Statement

Concept 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income -$10.56M -$10.26M
YoY Change 2.98% 26.41%
Depreciation, Depletion And Amortization $296.0K $179.0K
YoY Change 65.36% 8.48%
Cash From Operating Activities -$11.91M -$9.947M
YoY Change 19.71% 52.3%
INVESTING ACTIVITIES
Capital Expenditures $607.0K $1.543M
YoY Change -60.66% 915.13%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$607.0K -$2.917M
YoY Change -79.19% 410.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $31.60M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 32.71M
YoY Change
NET CHANGE
Cash From Operating Activities -11.91M -9.947M
Cash From Investing Activities -607.0K -2.917M
Cash From Financing Activities 32.71M
Net Change In Cash 20.20M -12.86M
YoY Change -257.01% 157.54%
FREE CASH FLOW
Cash From Operating Activities -$11.91M -$9.947M
Capital Expenditures $607.0K $1.543M
Free Cash Flow -$12.52M -$11.49M
YoY Change 8.92% 71.93%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2697000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4431000
CY2017Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2626000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3532000
CY2017Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
166000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
57000
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
724000
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1817000
CY2017Q1 us-gaap Assets
Assets
87616000
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54632000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34324000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
91051000
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
78225000
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
20308000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-12826000
CY2016Q4 us-gaap Assets
Assets
67050000
CY2017Q1 us-gaap Assets Current
AssetsCurrent
57085000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
36930000
CY2017Q1 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
0
CY2016Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
0
CY2017Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
101000
CY2016Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
405000
CY2017Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2016Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35215222
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32627691
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
276079000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
242419000
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10453000
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10219000
CY2017Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Concentrations of Credit Risk</div></div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents. The Company holds these investments in highly-rated financial institutions, and limits the amounts of credit exposure to any <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> financial institution. These amounts at times <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</div></div></div></div></div></div>
CY2017Q1 us-gaap Construction In Progress Expenditures Incurred But Not Yet Paid
ConstructionInProgressExpendituresIncurredButNotYetPaid
CY2016Q1 us-gaap Construction In Progress Expenditures Incurred But Not Yet Paid
ConstructionInProgressExpendituresIncurredButNotYetPaid
1963000
CY2017Q1 us-gaap Construction In Progress Gross
ConstructionInProgressGross
CY2016Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
19978000
CY2017Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
23000
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
23000
CY2017Q1 us-gaap Depreciation
Depreciation
296000
CY2016Q1 us-gaap Depreciation
Depreciation
179000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2017Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
110000
CY2016Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
38000
CY2017Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-341000
CY2016Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-9000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2083000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2436000
CY2017Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1835000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2348000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-905000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
250000
CY2017Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
CY2016Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
4000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-375000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-408000
CY2017Q1 us-gaap Investment Income Net
InvestmentIncomeNet
49000
CY2016Q1 us-gaap Investment Income Net
InvestmentIncomeNet
CY2017Q1 us-gaap Liabilities
Liabilities
5346000
CY2016Q4 us-gaap Liabilities
Liabilities
7986000
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
87616000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
67050000
CY2017Q1 us-gaap Liabilities Current
LiabilitiesCurrent
5323000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7963000
CY2017Q1 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
0
CY2016Q4 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
0
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32713000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-607000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2917000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10271000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10248000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11908000
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9947000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-10563000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-10257000
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-292000
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
10271000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
10248000
CY2017Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
110000
CY2016Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
38000
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
607000
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1543000
CY2017Q1 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2016Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2017Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2017Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2453000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2606000
CY2016Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1800000
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1000000
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
31600000
CY2017Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
93000
CY2016Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
CY2017Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
32620000
CY2016Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1100000
CY2017Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
30531000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10142000
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8188000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7812000
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-193975000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-183412000
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
204000
CY2017Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
66000
CY2017Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
66410
CY2017Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
315000
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
82270000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
724000
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1817000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
27125
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
23000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.24
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.01
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5188658
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5118123
CY2016Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
145000
CY2017Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
87000
CY2017Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2400000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
59064000
CY2017Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">The preparation of financial statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported values of amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Prior to its initial public offering on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> the Company utilized significant estimates and assumptions in determining the fair value of its common stock. The board of directors determined the estimated fair value of the Company&#x2019;s common stock based on a number of objective and subjective factors, including the prices at which the Company sold shares of its common stock to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> parties and external market conditions affecting the biotechnology industry sector. After the initial public offering, the fair market value is calculated by using the closing price of the Company&#x2019;s common stock as reported by NASDAQ.</div></div></div></div></div></div>
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33291672
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32292106
CY2017Q1 xbit Payments For Proceeds From Construction In Process
PaymentsForProceedsFromConstructionInProcess
0
CY2016Q1 xbit Payments For Proceeds From Construction In Process
PaymentsForProceedsFromConstructionInProcess
1374000
CY2017Q1 xbit Receivable On Issuance Of Common Stock Under Stock Option Plan
ReceivableOnIssuanceOfCommonStockUnderStockOptionPlan
223000
CY2016Q1 xbit Receivable On Issuance Of Common Stock Under Stock Option Plan
ReceivableOnIssuanceOfCommonStockUnderStockOptionPlan

Files In Submission

Name View Source Status
0001171843-17-002928-index-headers.html Edgar Link pending
0001171843-17-002928-index.html Edgar Link pending
0001171843-17-002928.txt Edgar Link pending
0001171843-17-002928-xbrl.zip Edgar Link pending
exh_311.htm Edgar Link pending
exh_312.htm Edgar Link pending
exh_321.htm Edgar Link pending
f10q_051017p.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xbit-20170331.xml Edgar Link completed
xbit-20170331.xsd Edgar Link pending
xbit-20170331_cal.xml Edgar Link unprocessable
xbit-20170331_def.xml Edgar Link unprocessable
xbit-20170331_lab.xml Edgar Link unprocessable
xbit-20170331_pre.xml Edgar Link unprocessable